Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Cholesterol Endpoints Draw Scrutiny At HoFH Panels

Oct 22 2012

• By Cathy Dombrowski and Martin Berman-Gorvine

Related Content

Off-Label Use Of Malaria Drug Drives FDA To Impose REMS

Jul 08 2010

The Role Of RiskMAPs: Fentora Shows Shift From Post-Market To Pre-Market

May 12 2008

Entereg Documents Offer Detailed Insight Into REMS Review Process

Oct 01 2008

Panel Review Of Aegerion’s Lomitapide May Lead To Evolution Of Cholesterol Drug Approval Standards

Oct 15 2012

FDA’s Decision To Back Off <em>Korlym</em> REMS Shows Context Is King

Sep 01 2012

Related Companies

Aegerion Pharmaceuticals, Inc.

Sanofi Genzyme

Ionis Pharmaceuticals, Inc.

Cubist Pharmaceuticals, Inc.

Cephalon, Inc.

Corcept Therapeutics Incorporated

Additional Topics

United States Advisory Committees BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window